NGNE: Neurogene, Inc.
Performance
NGNE -2.80%
Watchlist
Select an item
Summary
NGNE at a glance
NGNE returned -2.80% over the past year. Its worst drop in that year was -49.67%, smaller than 23% of stocks on Redstone, and its Sharpe ratio of 0.30 beats 41% of stocks on Redstone. It pays no dividends.
Current Drawdown
-39.31%
Rolling Volatility
103.02%
Actions
Metrics
Risk Indicators
Alpha7.15%
Beta1.64x
Sharpe0.30
Sortino0.46
Omega1.05
Calmar-0.06
Martin0.81
Profile
About NGNE
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning).
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $520M
- Listed
- Dec 2023
- Employees
- 131
- Headquarters
- New York, NY
- Website
- neurogene.com
Comparisons